Citadel Advisors »

Rapport Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $4.6M 153k 29.70
2025-03-31 $2.5M 252k 10.03
2024-12-31 $8.6M 488k 17.74
2024-09-30 $9.5M 488k 19.46
2024-06-30 $13M 593k 22.30

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Spdr Gold Tr Gold Shs Call Option (GLD)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
Strategy Cl A New Call Option (MSTR)
Alphabet Cap Stk Cl A Call Option (GOOGL)
UnitedHealth Call Option (UNH)
Palantir Technologies Cl A Call Option (PLTR)
Netflix Call Option (NFLX)

View all positions for Citadel Advisors

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
Sofinnova Ventures
Johnson & Johnson
Vanguard Group
BlackRock
Baker Bros. Advisors
Siren
Trv Gp Vi
Vestal Point Capital
Polar Capital Holdings

View all funds holding Rapport Therapeutics